2022 Annual Meeting | Industry Therapeutic Update from Genentech: Staying Ahead of the Curve: Considerations for COVID-19 Treatments in MS Patients

Date Wednesday 04/06/22

Time 07:00 PM - 10:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives COVID-19 vaccine updates, monoclonal antibody considerations in the prevention and treatment of COVID-19 in MS patients on DMTs a multidisciplinary approach. A light meal will be provided.
Panelists include: Dr. Jihad Slim, Dr. Clyde Markowitz, Dr. Sharon Stoll, Dr. John Osborne
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN.
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available 0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT	Speaker	Industry Therapeutic Update from Genentech: Staying Ahead of the Curve: Considerations for COVID-19 Treatments in MS Patients

Faculty Disclosures
Clyde E. Markowitz, MD	No disclosure on file
Sharon Stoll, DO	Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for roche Genentech. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi/genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Stoll has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for alexion. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Stoll has stock in BeCare Link LLC. Dr. Stoll has stock in Global Consult MS .
John Osborne	No disclosure on file

��ɫ��

��ɫ��